1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
Nov 06, 2018•1 hr 13 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.
Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277
Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527
Reporting harms: doi.org/10.1136/bmj.k4383
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast